Branchiooculofacial syndrome (BOFS) is a rare autosomal dominant multiple congenital anomaly disorder caused by heterozygous pathogenic variants in TFAP2A, which encodes the transcription factor AP-2 alpha. It is characterized by branchial (cervical or infra-/supra-auricular) skin defects that range from thin skin or hair patches to erythematous "hemangiomatous" lesions or weeping erosions; ocular anomalies including microphthalmia, anophthalmia, coloboma, cataract, and nasolacrimal duct stenosis/atresia; and a characteristic facial appearance with cleft lip or prominent philtral pillars ("pseudocleft lip"), broad nasal tip, hypertelorism/telecanthus, and malformed pinnae. Hearing loss from inner ear and/or petrous bone anomalies is common, and renal, thymic, ectodermal, and dental anomalies occur in a subset. Intellect is usually normal. BOFS is regarded as a neurocristopathy: TFAP2A acts in premigratory and migratory neural crest cells, and its haploinsufficiency or functional impairment disrupts morphogenesis of structures derived from the cranial neural crest and pharyngeal arches.
Ask a research question about Branchiooculofacial Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Branchiooculofacial Syndrome
creation_date: "2026-06-03T00:00:00Z"
category: Genetic
synonyms:
- BOFS
- Branchio-oculo-facial syndrome
- BOF syndrome
- Hemangiomatous branchial clefts-lip pseudocleft syndrome
description: >
Branchiooculofacial syndrome (BOFS) is a rare autosomal dominant multiple
congenital anomaly disorder caused by heterozygous pathogenic variants in
TFAP2A, which encodes the transcription factor AP-2 alpha. It is
characterized by branchial (cervical or infra-/supra-auricular) skin defects
that range from thin skin or hair patches to erythematous "hemangiomatous"
lesions or weeping erosions; ocular anomalies including microphthalmia,
anophthalmia, coloboma, cataract, and nasolacrimal duct stenosis/atresia;
and a characteristic facial appearance with cleft lip or prominent philtral
pillars ("pseudocleft lip"), broad nasal tip, hypertelorism/telecanthus, and
malformed pinnae. Hearing loss from inner ear and/or petrous bone anomalies
is common, and renal, thymic, ectodermal, and dental anomalies occur in a
subset. Intellect is usually normal. BOFS is regarded as a neurocristopathy:
TFAP2A acts in premigratory and migratory neural crest cells, and its
haploinsufficiency or functional impairment disrupts morphogenesis of
structures derived from the cranial neural crest and pharyngeal arches.
disease_term:
preferred_term: branchiooculofacial syndrome
term:
id: MONDO:0007235
label: branchiooculofacial syndrome
references:
- reference: PMID:21634087
title: "Branchiooculofacial Syndrome."
tags:
- GeneReviews
parents:
- Multiple congenital anomalies/dysmorphic syndrome
- Autosomal dominant disease
inheritance:
- name: Autosomal dominant
evidence:
- reference: PMID:21204207
reference_title: Genotype-phenotype analysis of the branchio-oculo-facial syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Branchio-oculo-facial syndrome (BOFS; OMIM#113620) is a rare autosomal dominant craniofacial disorder with variable expression."
explanation: BOFS is inherited in an autosomal dominant manner with variable expressivity.
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "BOFS is inherited in an autosomal dominant manner. De novo pathogenic variants are observed in 50%-60% of affected individuals."
explanation: GeneReviews confirms autosomal dominant inheritance with a high de novo rate.
pathophysiology:
- name: TFAP2A Haploinsufficiency Disrupts Cranial Neural Crest Development
description: >
BOFS is caused by heterozygous pathogenic variants in TFAP2A, encoding the
transcription factor AP-2 alpha. TFAP2A is expressed in premigratory and
migratory neural crest cells and regulates gene expression during
embryogenesis of the eye, ear, face, and related structures. Most BOFS
families carry missense variants clustered in the highly conserved exons 4
and 5 (basic DNA-binding domain); deletions, nonsense, splice-altering,
and regulatory (enhancer-disconnecting) variants also cause BOFS.
Functional studies show these mutations reduce transcriptional activity,
alter nuclear localization of AP-2 alpha, and can act as null, hypomorphic,
or dominant-negative (antimorphic) alleles. The combination of cleft
lip/palate, premature graying, coloboma, heterochromia irides, and ectopic
thymus is cited as evidence that BOFS is a neurocristopathy.
cell_types:
- preferred_term: cranial neural crest cell
term:
id: CL:0000333
label: migratory neural crest cell
biological_processes:
- preferred_term: Neural crest cell development
term:
id: GO:0014032
label: neural crest cell development
modifier: DECREASED
- preferred_term: Regulation of transcription by RNA polymerase II
term:
id: GO:0006357
label: regulation of transcription by RNA polymerase II
modifier: DECREASED
evidence:
- reference: PMID:18423521
reference_title: TFAP2A mutations result in branchio-oculo-facial syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Four additional BOFS patients were found to have de novo missense mutations in the highly conserved exons 4 and 5 (basic region of the DNA binding domain) of the TFAP2A gene in the candidate deleted region. We conclude BOFS is caused by mutations involving TFAP2A."
explanation: Original identification of TFAP2A coding mutations and a deletion as the cause of BOFS.
- reference: PMID:21204207
reference_title: Genotype-phenotype analysis of the branchio-oculo-facial syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We have identified a hotspot region in the highly conserved exons 4 and 5 of TFAP2A that harbors missense mutations in 27/30 (90%) families."
explanation: Missense variants cluster in the conserved DNA-binding domain in the large majority of BOFS families.
- reference: PMID:21204207
reference_title: Genotype-phenotype analysis of the branchio-oculo-facial syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The occurrence of CL/P, premature graying, coloboma, heterochromia irides, and ectopic thymus, are evidence for BOFS as a neurocristopathy."
explanation: The constellation of features supports a neural crest origin (neurocristopathy) for BOFS.
downstream:
- target: TFAP2 Regulation of Midfacial Neural Crest Gene Networks (ALX axis)
description: >-
Disrupted neural crest development is mediated in part by dysregulation of
the TFAP2-controlled ALX midface gene regulatory network.
- target: Branchial skin defect
causal_link_type: DIRECT
- target: Microphthalmia
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Anophthalmia
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Coloboma
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Cataract
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Nasolacrimal duct obstruction
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Asymmetric crying face
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Abnormal pinna morphology
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Hearing loss
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Temporal bone anomaly
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Renal anomaly
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Congenital heart defect
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Dental anomaly
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Ectopic thymus
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Premature graying of hair
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Reduced and Dominant-Negative AP-2 alpha Transcriptional Activity
description: >
Individual TFAP2A BOFS mutations within the DNA-binding region have
different effects on DNA binding but all significantly reduce
transcriptional activity. Mutant AP-2 alpha proteins show altered
nuclear:cytoplasmic distribution compared with the predominantly nuclear
wild-type protein, and several can exert dominant-negative activity on
wild-type AP-2 alpha. These differences mean individual variants can
generate null, hypomorphic, or antimorphic alleles, contributing to the
marked phenotypic variability of BOFS.
biological_processes:
- preferred_term: Regulation of DNA-templated transcription
term:
id: GO:0006355
label: regulation of DNA-templated transcription
modifier: DECREASED
evidence:
- reference: PMID:23578821
reference_title: Analysis of TFAP2A mutations in Branchio-Oculo-Facial Syndrome indicates functional complexity within the AP-2α DNA-binding domain.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "We show that although individual mutations have different effects on DNA binding, they all demonstrate significantly reduced transcriptional activities."
explanation: In vitro functional assays show BOFS DNA-binding-domain mutations reduce AP-2 alpha transcriptional activity.
- reference: PMID:23578821
reference_title: Analysis of TFAP2A mutations in Branchio-Oculo-Facial Syndrome indicates functional complexity within the AP-2α DNA-binding domain.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "all mutant derivatives have an altered nuclear:cytoplasmic distribution compared with the predominantly nuclear localization of wild-type AP-2α and several can exert a dominant-negative activity on the wild-type AP-2α protein"
explanation: Mutant AP-2 alpha mislocalizes and several variants act dominant-negatively, supporting an antimorphic mechanism.
- reference: PMID:23578821
reference_title: Analysis of TFAP2A mutations in Branchio-Oculo-Facial Syndrome indicates functional complexity within the AP-2α DNA-binding domain.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "the individual TFAP2A BOFS mutations can generate null, hypomorphic or antimorphic alleles"
explanation: BOFS variants span a functional spectrum, helping explain variable expressivity.
downstream:
- target: TFAP2A Haploinsufficiency Disrupts Cranial Neural Crest Development
description: >-
Reduced and dominant-negative AP-2 alpha transcriptional activity is the
molecular basis for impaired cranial neural crest development in BOFS.
- name: TFAP2 Regulation of Midfacial Neural Crest Gene Networks (ALX axis)
description: >
In mouse and zebrafish models, TFAP2 paralogs (Tfap2a and Tfap2b) regulate
midfacial development of the cranial neural crest. Concerted inactivation
in the neural crest produces a midfacial cleft and skeletal abnormalities,
with dysregulation of midface gene regulatory network components. TFAP2
factors directly and positively regulate the ALX transcription factor genes
(Alx1, Alx3, Alx4); loss of TFAP2 reduces ALX transcript levels. This
provides a developmental mechanism linking TFAP2A dysfunction to the
midfacial clefting characteristic of BOFS.
biological_processes:
- preferred_term: Neural crest cell migration
term:
id: GO:0001755
label: neural crest cell migration
evidence:
- reference: PMID:38063857
reference_title: TFAP2 paralogs regulate midfacial development in part through a conserved ALX genetic pathway.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "concerted inactivation of Tfap2a and Tfap2b in the murine neural crest, even during the late migratory phase, results in a midfacial cleft and skeletal abnormalities"
explanation: Mouse neural-crest TFAP2 loss recapitulates midfacial clefting, modeling a core BOFS feature.
- reference: PMID:38063857
reference_title: TFAP2 paralogs regulate midfacial development in part through a conserved ALX genetic pathway.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Alx1, Alx3 and Alx4 (ALX) transcript levels are reduced, whereas ChIP-seq analyses suggest TFAP2 family members directly and positively regulate ALX gene expression."
explanation: Identifies a direct TFAP2 to ALX regulatory axis downstream of TFAP2A in midface development.
downstream:
- target: Cleft lip
causal_link_type: DIRECT
- target: Cleft palate
causal_link_type: DIRECT
- target: Hypertelorism
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Broad nasal tip
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Upslanted palpebral fissures
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Dolichocephaly
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Upper lip pit
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
phenotypes:
- category: Physical
name: Branchial skin defect
description: >
Bilateral branchial (cervical or infra-/supra-auricular) skin defects,
ranging from thin skin or a hair patch to erythematous "hemangiomatous"
lesions or large weeping erosions. A cardinal feature of BOFS.
phenotype_term:
preferred_term: Branchial anomaly
term:
id: HP:0009794
label: Branchial anomaly
frequency: VERY_FREQUENT
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Branchiooculofacial syndrome (BOFS) is characterized by branchial (cervical or infra- or supra-auricular) skin defects that range from barely perceptible thin skin or hair patch to erythematous \"hemangiomatous\" lesions to large weeping erosions"
explanation: GeneReviews lists branchial skin defects as a defining feature of BOFS.
- category: Physical
name: Microphthalmia
description: >
Small eye(s), part of the spectrum of ocular anomalies in BOFS that also
includes anophthalmia.
phenotype_term:
preferred_term: Microphthalmia
term:
id: HP:0000568
label: Microphthalmia
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ocular anomalies that can include microphthalmia, anophthalmia, coloboma, cataract, and nasolacrimal duct stenosis/atresia"
explanation: GeneReviews lists microphthalmia among the ocular anomalies of BOFS.
- category: Physical
name: Anophthalmia
description: >
Absence of one or both eyes, at the severe end of the BOFS ocular spectrum.
phenotype_term:
preferred_term: Anophthalmia
term:
id: HP:0000528
label: Anophthalmia
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ocular anomalies that can include microphthalmia, anophthalmia, coloboma, cataract, and nasolacrimal duct stenosis/atresia"
explanation: GeneReviews lists anophthalmia among the ocular anomalies of BOFS.
- category: Physical
name: Coloboma
description: >
Ocular coloboma is part of the spectrum of ocular anomalies in BOFS.
phenotype_term:
preferred_term: Coloboma
term:
id: HP:0000589
label: Coloboma
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ocular anomalies that can include microphthalmia, anophthalmia, coloboma, cataract, and nasolacrimal duct stenosis/atresia"
explanation: GeneReviews lists coloboma among the ocular anomalies of BOFS.
- reference: PMID:32766183
reference_title: 'A Heterozygous Novel Mutation in TFAP2A Gene Causes Atypical Branchio-Oculo-Facial Syndrome With Isolated Coloboma of Choroid: A Case Report.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The mother (proband) presented with bilateral coloboma of choroid, whereas her daughter had a relatively severe phenotype and presented with larger bilateral choroid coloboma and high-vaulted arch."
explanation: A TFAP2A-confirmed family with choroidal coloboma illustrates the ocular-predominant BOFS spectrum.
- category: Physical
name: Cataract
description: >
Cataract is part of the BOFS ocular anomaly spectrum.
phenotype_term:
preferred_term: Cataract
term:
id: HP:0000518
label: Cataract
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ocular anomalies that can include microphthalmia, anophthalmia, coloboma, cataract, and nasolacrimal duct stenosis/atresia"
explanation: GeneReviews lists cataract among the ocular anomalies of BOFS.
- category: Physical
name: Nasolacrimal duct obstruction
description: >
Nasolacrimal duct stenosis or atresia is an ocular-adnexal anomaly in BOFS
that often requires surgical correction.
phenotype_term:
preferred_term: Nasolacrimal duct obstruction
term:
id: HP:0000579
label: Nasolacrimal duct obstruction
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ocular anomalies that can include microphthalmia, anophthalmia, coloboma, cataract, and nasolacrimal duct stenosis/atresia"
explanation: GeneReviews lists nasolacrimal duct stenosis/atresia among the ocular anomalies of BOFS.
- category: Physical
name: Cleft lip
description: >
Cleft lip, or prominent philtral pillars giving the appearance of a
repaired cleft lip ("pseudocleft lip"), with or without cleft palate, is a
cardinal craniofacial feature of BOFS (CL/P).
phenotype_term:
preferred_term: Cleft upper lip
term:
id: HP:0000204
label: Cleft upper lip
frequency: VERY_FREQUENT
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "cleft lip or prominent philtral pillars that give the appearance of a repaired cleft lip (formerly called \"pseudocleft lip\") with or without cleft palate"
explanation: GeneReviews describes cleft lip / pseudocleft lip as a characteristic facial anomaly of BOFS.
- category: Physical
name: Cleft palate
description: >
Cleft palate may accompany cleft lip in BOFS (CL/P).
phenotype_term:
preferred_term: Cleft palate
term:
id: HP:0000175
label: Cleft palate
evidence:
- reference: PMID:19764023
reference_title: Confirmation of TFAP2A gene involvement in branchio-oculo-facial syndrome (BOFS) and report of temporal bone anomalies.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Branchio-oculo-facial syndrome (BOFS) is an autosomal-dominant condition characterized by three main features, respectively: branchial defects, ocular anomalies, and craniofacial defects including cleft lip and/or palate (CL/P)."
explanation: Cleft lip and/or palate is a defining craniofacial feature of BOFS.
- category: Physical
name: Hypertelorism
description: >
Increased distance between the eyes, part of the characteristic BOFS facies.
phenotype_term:
preferred_term: Hypertelorism
term:
id: HP:0000316
label: Hypertelorism
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "facial anomalies that can include dolichocephaly, hypertelorism or telecanthus, broad nasal tip, upslanted palpebral fissures"
explanation: GeneReviews lists hypertelorism/telecanthus among BOFS facial anomalies.
- category: Physical
name: Broad nasal tip
description: >
A broad nasal tip is part of the characteristic facial appearance of BOFS.
phenotype_term:
preferred_term: Broad nasal tip
term:
id: HP:0000455
label: Broad nasal tip
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "facial anomalies that can include dolichocephaly, hypertelorism or telecanthus, broad nasal tip, upslanted palpebral fissures"
explanation: GeneReviews lists broad nasal tip among BOFS facial anomalies.
- category: Physical
name: Upslanted palpebral fissures
description: >
Upslanting palpebral fissures contribute to the characteristic BOFS facies.
phenotype_term:
preferred_term: Upslanted palpebral fissure
term:
id: HP:0000582
label: Upslanted palpebral fissure
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "facial anomalies that can include dolichocephaly, hypertelorism or telecanthus, broad nasal tip, upslanted palpebral fissures"
explanation: GeneReviews lists upslanted palpebral fissures among BOFS facial anomalies.
- category: Physical
name: Dolichocephaly
description: >
A long, narrow head shape is part of the characteristic BOFS facial
appearance.
phenotype_term:
preferred_term: Dolichocephaly
term:
id: HP:0000268
label: Dolichocephaly
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "facial anomalies that can include dolichocephaly, hypertelorism or telecanthus, broad nasal tip, upslanted palpebral fissures"
explanation: GeneReviews lists dolichocephaly among BOFS facial anomalies.
- category: Physical
name: Upper lip pit
description: >
Upper lip pits are among the characteristic facial anomalies of BOFS.
phenotype_term:
preferred_term: Upper lip pit
term:
id: HP:0100268
label: Upper lip pit
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "with or without cleft palate, upper lip pits, and lower facial weakness"
explanation: GeneReviews lists upper lip pits among the characteristic facial anomalies of BOFS.
- category: Physical
name: Asymmetric crying face
description: >
Lower facial weakness (asymmetric crying face or partial weakness of cranial
nerve VII) is described in BOFS.
phenotype_term:
preferred_term: Asymmetric crying face
term:
id: HP:0011333
label: Asymmetric crying face
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "lower facial weakness (asymmetric crying face or partial weakness of cranial nerve VII)"
explanation: GeneReviews describes lower facial weakness/asymmetric crying face in BOFS.
- category: Physical
name: Abnormal pinna morphology
description: >
Malformed and prominent pinnae are common in BOFS.
phenotype_term:
preferred_term: Abnormal pinna morphology
term:
id: HP:0000377
label: Abnormal pinna morphology
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Malformed and prominent pinnae and hearing loss from inner ear and/or petrous bone anomalies are common."
explanation: GeneReviews lists malformed/prominent pinnae as common in BOFS.
- category: Physical
name: Hearing loss
description: >
Hearing loss from inner ear and/or petrous (temporal) bone anomalies is
common in BOFS; conductive, sensorineural, and mixed hearing loss all occur.
phenotype_term:
preferred_term: Hearing impairment
term:
id: HP:0000365
label: Hearing impairment
frequency: FREQUENT
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Malformed and prominent pinnae and hearing loss from inner ear and/or petrous bone anomalies are common."
explanation: GeneReviews lists hearing loss from inner ear/petrous bone anomalies as common in BOFS.
- reference: PMID:21250552
reference_title: 'Clinical presentation and the presence of hearing impairment in branchio-oculo-facial syndrome: a new mutation in the TFAP2A gene.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Congenital conductive hearing impairments are described, including hearing rehabilitation and the results of ear surgery."
explanation: Documents congenital conductive hearing impairment in TFAP2A-confirmed BOFS patients.
- category: Physical
name: Temporal bone anomaly
description: >
CT temporal bone anomalies related to branchial arch defects are reported in
BOFS and aid differential diagnosis.
phenotype_term:
preferred_term: Abnormal temporal bone morphology
term:
id: HP:0009911
label: Abnormal temporal bone morphology
evidence:
- reference: PMID:19764023
reference_title: Confirmation of TFAP2A gene involvement in branchio-oculo-facial syndrome (BOFS) and report of temporal bone anomalies.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we present CT scan temporal bone anomalies in the familial cases, related to branchial arch defects, highlighting the importance of radiological investigations for differential diagnosis."
explanation: Documents temporal bone anomalies related to branchial arch defects in TFAP2A-confirmed BOFS.
- category: Physical
name: Renal anomaly
description: >
Renal structural anomalies (e.g., agenesis, dysplasia, vesicoureteral
reflux) occur in a subset (~35%) of individuals with BOFS.
phenotype_term:
preferred_term: Abnormal renal morphology
term:
id: HP:0012210
label: Abnormal renal morphology
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Standard treatments for hearing loss, renal malformations, dental manifestations, and congenital heart defects."
explanation: GeneReviews references renal malformations among BOFS manifestations requiring management.
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "assess for a recurrent urinary tract infection suggestive of vesicoureteral reflux"
explanation: GeneReviews surveillance recommends monitoring for vesicoureteral reflux, a renal-tract anomaly in BOFS.
- category: Physical
name: Congenital heart defect
description: >
Congenital heart defects occur in a subset of individuals with BOFS and are
listed among the manifestations requiring standard management.
phenotype_term:
preferred_term: Congenital heart defect
term:
id: HP:0001627
label: Abnormal heart morphology
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Standard treatments for hearing loss, renal malformations, dental manifestations, and congenital heart defects."
explanation: GeneReviews lists congenital heart defects among BOFS manifestations requiring management.
- category: Physical
name: Dental anomaly
description: >
Dental manifestations (abnormal tooth size, number, and malocclusion) occur
in BOFS and are monitored during surveillance.
phenotype_term:
preferred_term: Abnormality of the dentition
term:
id: HP:0000164
label: Abnormality of the dentition
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "assess teeth for size, number, carries, and malocclusion"
explanation: GeneReviews surveillance recommends assessing teeth for size, number, and malocclusion in BOFS.
- category: Physical
name: Ectopic thymus
description: >
Ectopic (dermal/cervical) thymic tissue is a characteristic finding in BOFS
and is one of the cardinal diagnostic criteria, consistent with a neural
crest / pharyngeal arch developmental defect.
phenotype_term:
preferred_term: Ectopic thymus tissue
term:
id: HP:0010517
label: Ectopic thymus tissue
evidence:
- reference: PMID:21204207
reference_title: Genotype-phenotype analysis of the branchio-oculo-facial syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we documented TFAP2A mutations in three (10%) probands in our series without a classic cervical cutaneous defect or ectopic thymus"
explanation: Ectopic thymus is one of the cardinal BOFS features in the diagnostic criteria.
- category: Physical
name: Premature graying of hair
description: >
Premature graying of hair is an ectodermal feature of BOFS, occurring in
roughly a third of patients, and contributes to the neurocristopathy
classification.
phenotype_term:
preferred_term: Premature graying of hair
term:
id: HP:0002216
label: Premature graying of hair
evidence:
- reference: PMID:21204207
reference_title: Genotype-phenotype analysis of the branchio-oculo-facial syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The occurrence of CL/P, premature graying, coloboma, heterochromia irides, and ectopic thymus, are evidence for BOFS as a neurocristopathy."
explanation: Premature graying is documented as a recurrent BOFS feature supporting neural crest involvement.
genetic:
- name: TFAP2A
gene_term:
preferred_term: TFAP2A
term:
id: hgnc:11742
label: TFAP2A
inheritance:
- name: Autosomal dominant
notes: >
Heterozygous pathogenic variants in TFAP2A (encoding transcription factor
AP-2 alpha; gene OMIM 107580, locus 6p24.3) cause autosomal dominant BOFS.
The mutational spectrum includes recurrent missense variants in the
conserved DNA-binding domain (exons 4-5), nonsense and splice variants,
small indels/frameshifts, whole- or multi-exon deletions (including a
3.2 Mb deletion in the original family), and mosaicism. No genetic
heterogeneity has been established.
evidence:
- reference: PMID:18423521
reference_title: TFAP2A mutations result in branchio-oculo-facial syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We detected a 3.2 Mb deletion by 500K SNP microarray in an affected mother and son with BOFS at chromosome 6p24.3."
explanation: Identifies the TFAP2A locus (6p24.3) and a causative deletion in BOFS.
- reference: PMID:21204207
reference_title: Genotype-phenotype analysis of the branchio-oculo-facial syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Several of these mutations are recurrent. Mosaicism was detected in one family. To date, genetic heterogeneity has not been observed."
explanation: Documents recurrent variants, mosaicism, and absence of locus heterogeneity in BOFS.
- reference: PMID:29760939
reference_title: Novel TFAP2A mutation in a Japanese family with Branchio-oculo-facial syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "BOFS is caused by mutation of the transcription factor AP2-alpha gene (TFAP2A)."
explanation: Confirms TFAP2A as the causative gene; identifies a novel missense variant in the conserved DNA-binding domain.
- reference: PMID:32766183
reference_title: 'A Heterozygous Novel Mutation in TFAP2A Gene Causes Atypical Branchio-Oculo-Facial Syndrome With Isolated Coloboma of Choroid: A Case Report.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "a novel nonsense mutation c.912C>A, p.(Cys304*) (NM_001042425.2) which in exon 6 of the conserved helix-span-helix domain in TFAP2A results in a premature termination codon. It may trigger nonsense-mediated mRNA decay (NMD)."
explanation: Demonstrates a nonsense/loss-of-function TFAP2A mechanism (NMD) causing BOFS.
treatments:
- name: Multidisciplinary craniofacial care
description: >
Children with BOFS are best managed by a multispecialty team including
craniofacial specialists, plastic surgeons, otolaryngologists, and
speech-language therapists.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In general, children with BOFS should be managed by a multispecialty team including craniofacial specialists, plastic surgeons, otolaryngologists, and speech-language therapists."
explanation: GeneReviews recommends multidisciplinary craniofacial management for BOFS.
- name: Cleft lip repair
description: >
Surgical repair of cleft lip by an experienced pediatric plastic surgeon.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It is recommended that cleft lip be repaired by an experienced pediatric plastic surgeon."
explanation: GeneReviews recommends surgical cleft lip repair in BOFS.
- name: Nasolacrimal duct surgery
description: >
Nasolacrimal duct stenosis or atresia often requires surgical correction.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Nasolacrimal duct stenosis or atresia often requires surgery."
explanation: GeneReviews indicates surgical management of nasolacrimal duct obstruction in BOFS.
- name: Hearing rehabilitation
description: >
Standard treatments for hearing loss, including hearing rehabilitation and
ear surgery; bone-anchored hearing aids have been used for conductive loss.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: PMID:21250552
reference_title: 'Clinical presentation and the presence of hearing impairment in branchio-oculo-facial syndrome: a new mutation in the TFAP2A gene.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Congenital conductive hearing impairments are described, including hearing rehabilitation and the results of ear surgery."
explanation: Documents hearing rehabilitation and ear surgery in TFAP2A-confirmed BOFS patients.
- name: Genetic counseling
description: >
BOFS is autosomal dominant with a 50% recurrence risk to offspring; de novo
variants occur in 50%-60%. Once the familial TFAP2A variant is identified,
prenatal and preimplantation genetic testing are possible.
treatment_term:
preferred_term: Genetic Counseling
term:
id: NCIT:C15240
label: Genetic Counseling
evidence:
- reference: PMID:21634087
reference_title: Branchiooculofacial Syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Once the TFAP2A pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible."
explanation: GeneReviews describes reproductive genetic counseling options for BOFS families.
datasets: []
BOFS is a rare, multisystem congenital craniofacial developmental disorder classically involving branchial cutaneous defects, ocular anomalies, and craniofacial anomalies (especially clefting) (milunsky2008tfap2amutationsresult pages 1-2, min2020aheterozygousnovel pages 1-2). Recent curated summary text notes that “Most individuals with branchiooculofacial syndrome (BOFS) can be diagnosed in infancy on the basis of their clinical features.” (haldemanenglert2025branchiooculofacialsyndrome pages 4-7).
A concise definition from a molecularly confirmed family report states BOFS is “a rare autosomal dominant disorder characterized by craniofacial, ocular, and ectodermal anomalies” (Human Genome Variation 2018-05; URL https://doi.org/10.1038/s41439-018-0004-z) (sato2018noveltfap2amutation pages 1-3).
The BOFS knowledge here is derived mainly from aggregated disease-level resources (GeneReviews-style summary excerpts), cohort studies, and case reports, rather than EHR-derived cohorts (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, milunsky2011genotype–phenotypeanalysisof pages 1-2).
Primary cause: heterozygous pathogenic variants affecting TFAP2A (autosomal dominant), including coding variants, deletions/duplications, mosaicism, and regulatory structural variants that disrupt TFAP2A enhancer contacts (milunsky2008tfap2amutationsresult pages 1-2, milunsky2011genotype–phenotypeanalysisof pages 1-2, shi2023structuralvariantsinvolved pages 1-2).
Direct human genetic evidence for causality includes discovery of a 3.2 Mb deletion including TFAP2A and multiple de novo TFAP2A missense variants in BOFS patients (AJHG 2008-05; URL https://doi.org/10.1016/j.ajhg.2008.03.005) (milunsky2008tfap2amutationsresult pages 1-2).
No protective genetic or environmental factors were identified in the available evidence.
No gene–environment interaction evidence was identified in the retrieved texts.
BOFS is defined by three major domains: branchial defects, ocular anomalies, and craniofacial anomalies (notably cleft lip/microform cleft) (stoetzel2009confirmationoftfap2a pages 1-2, min2020aheterozygousnovel pages 1-2).
A curated summary incorporating a large ophthalmic review (172 individuals) reports approximate frequencies: - Cervical cutaneous defects: ~90% - Infra-/supra-auricular defects: ~60% - Cleft lip / microform cleft lip (with or without cleft palate): 99% (no isolated cleft palate reported) - Hearing loss: ~70% - Renal structural anomalies: ~35% - Thymic anomalies: ~35% - Ocular findings (172-case review): nasolacrimal duct stenosis 57%, coloboma 46%, anophthalmia/microphthalmia 37%, cataract 16%, strabismus 14%, myopia 12% (haldemanenglert2025branchiooculofacialsyndrome pages 4-7).
Additional tabulated frequencies from older clinical compilation include: - Ectodermal anomalies: 37/62 (60%) - Dental anomalies: 23/55 (42%) - Prematurely gray hair: 20/53 (38%) - Malformed middle/inner ear: 10/27 (37%) - Kidney anomaly: 17/48 (35%) - Growth retardation: 18/62 (29%) - Congenital heart disease: 3/37 (8%) - Intellectual disability/mental retardation: 8/56 (14%) (lugli2015earlydiagnosisof pages 4-4).
Direct QoL instrument data (EQ-5D/SF-36) were not identified. However, the functional burden is implied by frequent visual and hearing handicaps and by explicit psychosocial surveillance recommendations: “Monitor for signs of low self-esteem & other psychologic issues.” (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, milunsky2011genotype–phenotypeanalysisof pages 7-7).
Representative HPO mappings (non-exhaustive; based on described phenotypes in retrieved evidence): - Branchial/cutaneous: Branchial fistula (HP:0009795); Cervical sinus (HP:0009796); Aplasia cutis congenita (if present); Ectopic thymus (no single canonical HP term; map via “Thymus hypoplasia/abnormality” as appropriate) (thomeer2010clinicalpresentationand pages 4-6, lugli2015earlydiagnosisof pages 1-3). - Craniofacial: Cleft lip (HP:0000204); Cleft palate (HP:0000175); Broad nasal bridge (HP:0000431); Hypertelorism (HP:0000316); Telecanthus (HP:0000506); Dolichocephaly (HP:0000268) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7, min2020aheterozygousnovel pages 1-2). - Ocular: Microphthalmia (HP:0000568); Anophthalmia (HP:0000528); Coloboma (HP:0000589); Congenital cataract (HP:0000519); Strabismus (HP:0000486); Nasolacrimal duct obstruction (HP:0000579) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7, min2020aheterozygousnovel pages 1-2). - Auditory/temporal bone: Hearing impairment (HP:0000365); Conductive hearing impairment (HP:0000405); Sensorineural hearing impairment (HP:0000407); Abnormality of the ossicles (HP:0000380) (thomeer2010clinicalpresentationand pages 4-6). - Renal: Renal agenesis (HP:0000104); Multicystic dysplastic kidney (HP:0000003); Vesicoureteral reflux (HP:0000076) (milunsky2011genotype–phenotypeanalysisof pages 9-10). - Ectodermal: Premature graying of hair (HP:0002216); Dental anomalies (HP:0000164); Nail dystrophy (HP:0002164) (lugli2015earlydiagnosisof pages 4-4).
Reported pathogenic mechanisms include: - Missense (dominant class; hotspot in exons 4–5) (milunsky2011genotype–phenotypeanalysisof pages 1-2, milunsky2011genotype–phenotypeanalysisof pages 6-7) - Nonsense (example: c.912C>A, p.Cys304) (Front Pediatr 2020-07; URL https://doi.org/10.3389/fped.2020.00380) (min2020aheterozygousnovel pages 1-2) - Frameshift / small indels (reported in curated summary) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7) - Splice-altering variants (including predicted creation of a new splice acceptor in one report) (reiber2010additionalclinicaland pages 3-5) - Large deletions/CNVs including a 3.2 Mb deletion encompassing TFAP2A (milunsky2008tfap2amutationsresult pages 1-2, milunsky2011genotype–phenotypeanalysisof pages 1-2) - Regulatory structural variants*: an inversion disconnecting TFAP2A from enhancers (cited as causative) (shi2023structuralvariantsinvolved pages 1-2)
A large cohort identified a strong hotspot in conserved exons 4–5 with multiple recurrent amino acid substitutions, including R254 changes, R237 changes, E242K, G251E, R255G, and A256V (milunsky2011genotype–phenotypeanalysisof pages 6-7). A separate study also reports c.763A>G (p.Arg255Gly) as a probable mutational hotspot (reiber2010additionalclinicaland pages 1-2).
Population allele frequencies (e.g., gnomAD) and ClinVar aggregate counts were not available in the retrieved full-text excerpts and cannot be reliably reported here.
No environmental, lifestyle, or infectious contributors have been reported in the retrieved sources; BOFS is best supported as a genetic developmental disorder (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, min2020aheterozygousnovel pages 1-2).
Upstream trigger: heterozygous TFAP2A loss-of-function or impaired regulation (coding variant, deletion, mosaicism, or enhancer disconnection) (milunsky2008tfap2amutationsresult pages 1-2, shi2023structuralvariantsinvolved pages 1-2).
Molecular role of TFAP2A: TFAP2A is a retinoic acid–responsive AP-2 family transcription factor, expressed in premigratory and migratory neural crest cells, regulating gene expression during embryogenesis of the eye, ear, face, limbs, body wall, and neural tube; it is also “required for early morphogenesis of the lens” (haldemanenglert2025branchiooculofacialsyndrome pages 11-14).
Downstream developmental disruption: 2024 mechanistic work shows TFAP2 paralogs regulate cranial neural crest midfacial development partly by directly activating ALX transcription factor genes (Alx1/Alx3/Alx4) (Development 2024-01; URL https://doi.org/10.1242/dev.202095). Loss of TFAP2 function reduces Alx transcripts and dysregulates broader midface gene regulatory network components; these changes are linked to midfacial clefts and craniofacial skeletal abnormalities in mouse and zebrafish models (nguyen2024tfap2paralogsregulate pages 1-3, nguyen2024tfap2paralogsregulate pages 7-9).
Regulatory SV mechanism: A high-quality 2023 structural variation paper explicitly notes that “an inversion disconnecting TFAP2A from its enhancers causes branchiooculofacial syndrome,” supporting that disrupted long-range enhancer–promoter regulation can phenocopy coding loss-of-function in BOFS (Nature Communications 2023-12; URL https://doi.org/10.1038/s41467-023-44034-z) (shi2023structuralvariantsinvolved pages 1-2).
GO Biological Process (examples): - Neural crest cell development / differentiation / migration - Craniofacial morphogenesis - Eye development; lens morphogenesis - Regulation of transcription (DNA-templated)
Cell Ontology (CL) (examples): - Cranial neural crest cell (CNCC)
UBERON (examples): - Pharyngeal arch derivatives (first and second pharyngeal arches) - Eye, lens, inner ear, midface
Evidence types: human genetic causality (milunsky2008tfap2amutationsresult pages 1-2); animal model mechanistic pathway mapping (mouse + zebrafish) (nguyen2024tfap2paralogsregulate pages 1-3, nguyen2024tfap2paralogsregulate pages 7-9).
Primary systems: - Craniofacial/orofacial (cleft lip ± cleft palate; characteristic facial morphology) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7, min2020aheterozygousnovel pages 1-2) - Ocular (microphthalmia/anophthalmia, coloboma, cataract, strabismus, nasolacrimal duct obstruction) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7) - Auditory/temporal bone (hearing loss; middle/inner ear malformations; external canal anomalies) (thomeer2010clinicalpresentationand pages 4-6, lugli2015earlydiagnosisof pages 4-4) Secondary/variable: - Renal anomalies (~35%) (milunsky2011genotype–phenotypeanalysisof pages 9-10, haldemanenglert2025branchiooculofacialsyndrome pages 4-7) - Thymic anomalies (~35%) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7) - Ectodermal appendages (hair, teeth, nails) (lugli2015earlydiagnosisof pages 4-4)
Robust prevalence/incidence statistics were not found in the retrieved evidence. Case-count statements indicate rarity, with older and newer summaries noting roughly ~50 cases in older literature and <150 well-described cases in later reports/curated summaries (reiber2010additionalclinicaland pages 1-2, min2020aheterozygousnovel pages 1-2).
Clinical diagnosis may be made by recognizing the triad of branchial, ocular, and craniofacial features; atypical presentations exist and motivate molecular confirmation (min2020aheterozygousnovel pages 1-2, lugli2015earlydiagnosisof pages 1-3).
A curated diagnostic workflow recommends: 1) TFAP2A sequence analysis first, and 2) if negative, gene-targeted deletion/duplication analysis to detect exon- or whole-gene CNVs (haldemanenglert2025branchiooculofacialsyndrome pages 1-4).
Testing options include single-gene testing, multigene panels, and exome/genome sequencing (haldemanenglert2025branchiooculofacialsyndrome pages 1-4).
In an EJHG 2024 study of individuals with orofacial clefts plus microphthalmia/anophthalmia/coloboma (OC+MAC), WES provided a conclusive diagnosis in 6/17 (35.29%), including a TFAP2A/BOFS diagnosis, while CMA detected no pathogenic/likely pathogenic CNVs (Publication date: 2024-11; URL https://doi.org/10.1038/s41431-023-01488-5) (tacla2024molecularinvestigationin pages 1-2).
No disease-modifying pharmacologic therapy is established in the retrieved evidence; management is supportive and surgical.
A curated summary recommends that affected children be managed by a multispecialty craniofacial team and notes interventions including: - Nasolacrimal duct surgery for stenosis/atresia - Cleft lip repair by experienced pediatric plastic surgeons - Orbital conformer for anophthalmia/severe microphthalmia - Standard-of-care management for hearing loss, renal malformations, dental manifestations, congenital heart defects (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, haldemanenglert2025branchiooculofacialsyndrome pages 9-11).
A detailed otologic case series documents real-world implementation for conductive hearing loss: CT temporal bone imaging; canal/middle ear surgeries; and bone-anchored hearing aid (BAHA) implantation with postoperative audiometric improvement (thomeer2010clinicalpresentationand pages 4-6).
BOFS prevention is primarily genetic and surveillance-based: - Primary prevention / reproductive options: prenatal and preimplantation genetic testing once a familial TFAP2A pathogenic variant is identified (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, haldemanenglert2025branchiooculofacialsyndrome pages 1-4). - Secondary prevention: evaluation of at-risk relatives and surveillance to detect treatable complications (hearing, vision, renal) (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, haldemanenglert2025branchiooculofacialsyndrome pages 9-11). - Tertiary prevention: timely surgical correction and supportive therapies to minimize disability (thomeer2010clinicalpresentationand pages 4-6, haldemanenglert2025branchiooculofacialsyndrome pages 1-4).
No naturally occurring veterinary BOFS analogs were identified in the retrieved evidence.
Recent mechanistic work uses mouse and zebrafish models to study TFAP2 function in cranial neural crest and midfacial development, demonstrating clefting and dysregulated ALX pathway activity after Tfap2 perturbation (nguyen2024tfap2paralogsregulate pages 1-3, nguyen2024tfap2paralogsregulate pages 7-9).
1) BOFS is best conceptualized as a neural-crest–related developmental disorder (neurocristopathy) driven by haploinsufficiency or functional impairment of TFAP2A, with broad effects on gene regulatory networks controlling facial, ocular, and ear morphogenesis (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, nguyen2024tfap2paralogsregulate pages 1-3). 2) Variant interpretation and test selection must explicitly account for both coding and non-coding mechanisms. In addition to recurrent missense hotspots (exons 4–5), large deletions and enhancer-disconnecting inversions can cause BOFS; therefore, negative sequencing should prompt CNV/structural variant evaluation when suspicion remains high (milunsky2011genotype–phenotypeanalysisof pages 6-7, milunsky2008tfap2amutationsresult pages 1-2, shi2023structuralvariantsinvolved pages 1-2). 3) Real-world practice increasingly relies on exome sequencing and integrated craniofacial care, supported by a 2024 cohort demonstrating meaningful WES diagnostic yield in complex cranio-ocular phenotypes that included BOFS (tacla2024molecularinvestigationin pages 1-2) and by detailed otologic management examples showing benefit of advanced hearing interventions (thomeer2010clinicalpresentationand pages 4-6).
| Category | Key data |
|---|---|
| Identifiers | Disease: Branchio-oculo-facial syndrome (BOFS), OMIM 113620; Gene: TFAP2A (OMIM 107580), locus 6p24.3 in recent GeneReviews-style summary; older papers also reported mapping as 6p21.3. Synonym: branchiooculofacial syndrome / BOF syndrome (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, sato2018noveltfap2amutation pages 1-3, reiber2010additionalclinicaland pages 1-2) |
| Inheritance / de novo / penetrance | Autosomal dominant; ~40%–50% have an affected parent and ~50%–60% are due to de novo TFAP2A variants; penetrance described as almost complete with marked intra-/interfamilial variable expressivity; parental somatic/germline mosaicism is a recurrence-risk consideration (haldemanenglert2025branchiooculofacialsyndrome pages 11-14) |
| Hallmark phenotypes | Typical diagnosis is congenital/infancy. Major domains: branchial cutaneous defects, ocular anomalies, and craniofacial/cleft phenotype. Frequencies from aggregated BOFS summaries: cervical cutaneous defects ~90%, infra-/supra-auricular defects ~60%, cleft lip / microform cleft with or without cleft palate ~99%, hearing loss ~70%, renal structural anomalies ~35%, thymic anomalies ~35%, premature graying/poliosis ~35%. Ocular frequencies from 172-case review summarized in GeneReviews: nasolacrimal duct stenosis 57%, coloboma 46%, anophthalmia/microphthalmia 37%, cataract 16%, strabismus 14%, myopia 12% (haldemanenglert2025branchiooculofacialsyndrome pages 4-7) |
| Additional phenotype statistics | From older BOFS tabulation: ectodermal anomalies 37/62 (60%); dental anomalies 23/55 (42%); nail anomalies 8/61 (13%); prematurely gray hair 20/53 (38%); malformed middle/inner ear 10/27 (37%); kidney anomaly 17/48 (35%); growth retardation 18/62 (29%); congenital heart disease 3/37 (8%); intellectual disability/mental retardation 8/56 (14%). Psychomotor development is usually normal despite sensory handicaps; developmental delay/autism are uncommon (lugli2015earlydiagnosisof pages 4-4, haldemanenglert2025branchiooculofacialsyndrome pages 4-7, milunsky2011genotype–phenotypeanalysisof pages 7-7) |
| Genetic mechanisms | BOFS is caused by heterozygous TFAP2A alterations. Pathogenic mechanisms include missense SNVs (dominant mechanism in most families), nonsense variants, splice-altering variants, small indels/frameshifts, whole-/multi-exon deletions, and mosaicism. A historical cohort found missense variants in 27/30 families (90%) and one 3.2 Mb deletion including TFAP2A; no clear genotype-phenotype correlation established (milunsky2011genotype–phenotypeanalysisof pages 1-2, haldemanenglert2025branchiooculofacialsyndrome pages 4-7) |
| Recurrent variants / hotspots | Strong hotspot in exons 4–5 (DNA-binding/basic region), with recurrent amino-acid substitutions including R254G/W/P (6), R237G/P (3), E242K (3), G251E (2), R255G (2), A256V (3); recurrent c.763A>G (p.Arg255Gly) reported as probable hotspot. Other reported BOFS variants include p.Arg236Pro, p.Leu269Pro, p.Glu296Lys, p.Cys304*, and family-specific missense/nonsense changes. Variant clustering supports prioritizing exons 4–6 in review, but broader testing remains necessary (milunsky2011genotype–phenotypeanalysisof pages 6-7, reiber2010additionalclinicaland pages 3-5, milunsky2008tfap2amutationsresult pages 1-2, min2020aheterozygousnovel pages 1-2, thomeer2010clinicalpresentationand pages 4-6, sato2018noveltfap2amutation pages 1-3) |
| Structural/regulatory mechanisms | Structural/regulatory disruption is relevant: a 2023 Nature Communications paper cites prior evidence that “an inversion disconnecting TFAP2A from its enhancers causes branchiooculofacial syndrome.” This supports enhancer-domain disruption as a bona fide disease mechanism in addition to coding variants (shi2023structuralvariantsinvolved pages 1-2) |
| Mechanistic understanding | TFAP2A encodes AP-2α, a transcription factor active in premigratory and migratory neural crest cells and important for embryogenesis of the eye, ear, face, limbs, body wall, and neural tube. 2024 developmental work showed TFAP2 paralogs regulate midfacial development partly via a conserved ALX pathway: Alx1/3/4 transcript levels fall with Tfap2 loss, and ChIP-seq supports direct positive regulation of ALX loci (nguyen2024tfap2paralogsregulate pages 1-3, haldemanenglert2025branchiooculofacialsyndrome pages 11-14) |
| Diagnostic workflow | Recommended order: TFAP2A sequence analysis first; if negative, perform gene-targeted deletion/duplication analysis because sequencing may miss exon- or whole-gene CNVs. Acceptable strategies include single-gene testing, multigene craniofacial/ocular panels, and exome/genome sequencing. Sequence analysis detects the vast majority (>95%) of pathogenic variants in the GeneReviews-style summary; del/dup testing accounts for a minority (<5%) but is still important (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, haldemanenglert2025branchiooculofacialsyndrome pages 4-7) |
| Diagnostic yield evidence (recent) | In a 2024 cohort of 17 individuals with orofacial cleft + microphthalmia/anophthalmia/coloboma (OC+MAC), WES gave a conclusive diagnosis in 6/17 (35.29%), including a TFAP2A/BOFS diagnosis; CMA detected no pathogenic/likely pathogenic CNVs in that cohort. Authors concluded WES was the most effective molecular approach for OC+MAC (tacla2024molecularinvestigationin pages 1-2) |
| Real-world management | Multidisciplinary craniofacial care is recommended: pediatric plastic surgery/cleft team, ENT/audiology, ophthalmology, nephrology as indicated, speech-language therapy, dental care, and psychosocial support. Interventions include nasolacrimal duct surgery, cleft lip repair, possible repair/reconstruction of branchial defects/pinnae, orbital conformer for anophthalmia/severe microphthalmia, and standard treatment of hearing, renal, cardiac, and dental problems (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, haldemanenglert2025branchiooculofacialsyndrome pages 7-9, haldemanenglert2025branchiooculofacialsyndrome pages 9-11) |
| Real-world hearing interventions | Case-level implementation includes full audiologic workup, CT temporal bone imaging, canal surgery, tympanotomy/ossicular procedures, myringoplasty, meatoplasty, and bone-anchored hearing aid (BAHA) placement with postoperative audiometric improvement; aggressive hearing evaluation is advised because conductive, sensorineural, and mixed hearing loss all occur (thomeer2010clinicalpresentationand pages 4-6, milunsky2011genotype–phenotypeanalysisof pages 9-10) |
Table: This table condenses the main disease-knowledge-base fields for Branchio-oculo-facial syndrome, including identifiers, phenotype frequencies, TFAP2A variant mechanisms, testing workflow, and practical management points. It emphasizes recent diagnostic and mechanistic evidence while anchoring claims to primary BOFS literature and curated summaries.
(These are the most central sources used in this report; additional sources are embedded in citations above.) - Milunsky JM et al. Am J Hum Genet. 2008-05. “TFAP2A mutations result in branchio-oculo-facial syndrome.” https://doi.org/10.1016/j.ajhg.2008.03.005 (milunsky2008tfap2amutationsresult pages 1-2) - Milunsky JM et al. Am J Med Genet A. 2011-01. “Genotype–phenotype analysis of the branchio-oculo-facial syndrome.” https://doi.org/10.1002/ajmg.a.33783 (milunsky2011genotype–phenotypeanalysisof pages 1-2, milunsky2011genotype–phenotypeanalysisof pages 9-10) - Tacla MA et al. Eur J Hum Genet. 2024-11. “Molecular investigation in individuals with orofacial clefts and microphthalmia-anophthalmia-coloboma spectrum.” https://doi.org/10.1038/s41431-023-01488-5 (tacla2024molecularinvestigationin pages 1-2) - Nguyen TT et al. Development. 2024-01. “TFAP2 paralogs regulate midfacial development in part through a conserved ALX genetic pathway.” https://doi.org/10.1242/dev.202095 (nguyen2024tfap2paralogsregulate pages 1-3, nguyen2024tfap2paralogsregulate pages 7-9) - Shi J et al. Nat Commun. 2023-12. “Structural variants involved in high-altitude adaptation…” (includes BOFS regulatory SV statement). https://doi.org/10.1038/s41467-023-44034-z (shi2023structuralvariantsinvolved pages 1-2) - Thomeer HGXM et al. Ann Otol Rhinol Laryngol. 2010-12. “Clinical Presentation…hearing impairment…” https://doi.org/10.1177/000348941011901204 (thomeer2010clinicalpresentationand pages 4-6)
References
(sato2018noveltfap2amutation pages 1-3): Taisuke Sato, Osamu Samura, Noriko Kato, Kosuke Taniguchi, Ken Takahashi, Yuki Ito, Hiroaki Aoki, Masahisa Kobayashi, Ohsuke Migita, Aikou Okamoto, and Kenichiro Hata. Novel tfap2a mutation in a japanese family with branchio-oculo-facial syndrome. Human Genome Variation, May 2018. URL: https://doi.org/10.1038/s41439-018-0004-z, doi:10.1038/s41439-018-0004-z. This article has 19 citations.
(haldemanenglert2025branchiooculofacialsyndrome pages 1-4): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.
(min2020aheterozygousnovel pages 1-2): Jie Min, Bing Mao, Yong Wang, Xuelian He, Shuyang Gao, and Hairong Wang. A heterozygous novel mutation in tfap2a gene causes atypical branchio-oculo-facial syndrome with isolated coloboma of choroid: a case report. Frontiers in Pediatrics, Jul 2020. URL: https://doi.org/10.3389/fped.2020.00380, doi:10.3389/fped.2020.00380. This article has 8 citations.
(haldemanenglert2025branchiooculofacialsyndrome pages 4-7): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.
(milunsky2008tfap2amutationsresult pages 1-2): Jeff M. Milunsky, Tom A. Maher, Geping Zhao, Amy E. Roberts, Heather J. Stalker, Roberto T. Zori, Michelle N. Burch, Michele Clemens, John B. Mulliken, Rosemarie Smith, and Angela E. Lin. Tfap2a mutations result in branchio-oculo-facial syndrome. American journal of human genetics, 82 5:1171-7, May 2008. URL: https://doi.org/10.1016/j.ajhg.2008.03.005, doi:10.1016/j.ajhg.2008.03.005. This article has 258 citations and is from a highest quality peer-reviewed journal.
(reiber2010additionalclinicaland pages 1-2): Judith Reiber, Yves Sznajer, Elena Guillén Posteguillo, Dietmar Müller, Stanislas Lyonnet, Clarisse Baumann, and Walter Just. Additional clinical and molecular analyses of tfap2a in patients with the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 152A:994-999, Apr 2010. URL: https://doi.org/10.1002/ajmg.a.33331, doi:10.1002/ajmg.a.33331. This article has 31 citations.
(haldemanenglert2025branchiooculofacialsyndrome pages 11-14): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.
(milunsky2011genotype–phenotypeanalysisof pages 1-2): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.
(shi2023structuralvariantsinvolved pages 1-2): Jinlong Shi, Zhilong Jia, Jinxiu Sun, Xiaoreng Wang, Xiaojing Zhao, Chenghui Zhao, Fan Liang, Xinyu Song, Jiawei Guan, Xue Jia, Jing Yang, Qi Chen, Kang Yu, Qian Jia, Jing Wu, Depeng Wang, Yuhui Xiao, Xiaoman Xu, Yinzhe Liu, Shijing Wu, Qin Zhong, Jue Wu, Saijia Cui, Xiaochen Bo, Zhenzhou Wu, Minsung Park, Manolis Kellis, and Kunlun He. Structural variants involved in high-altitude adaptation detected using single-molecule long-read sequencing. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-44034-z, doi:10.1038/s41467-023-44034-z. This article has 41 citations and is from a highest quality peer-reviewed journal.
(stoetzel2009confirmationoftfap2a pages 1-2): C. Stoetzel, S. Riehm, V. B. Greene, V. Pelletier, J. Vigneron, Bruno Leheup, Vincent Marion, Sophie Hellé, Jean-Marc Danse, C. Thibault, Luc Moulinier, F. Veillon, and Hélène Dollfus. Confirmation of tfap2a gene involvement in branchio‐oculo‐facial syndrome (bofs) and report of temporal bone anomalies. American Journal of Medical Genetics Part A, 149A:2141-2146, Oct 2009. URL: https://doi.org/10.1002/ajmg.a.33015, doi:10.1002/ajmg.a.33015. This article has 44 citations.
(lugli2015earlydiagnosisof pages 4-4): Licia Lugli, Walter Just, Elisabetta Genovese, Silvia Palma, Fabrizio Ferrari, and Antonio Percesepe. Early diagnosis of branchio-oculo-facial syndrome in a patient with inner ear malformation and mild ocular involvement. Clinical Dysmorphology, 24:17–20, Jan 2015. URL: https://doi.org/10.1097/mcd.0000000000000061, doi:10.1097/mcd.0000000000000061. This article has 1 citations and is from a peer-reviewed journal.
(ng2019tfap2amutationin pages 4-4): Pamela Si-Min Ng, Shazia Khan, Jiin Ying Lim, Jasmine Chew-Yin Goh, Grace Xiulin Lin, Heming Wei, Ene Choo Tan, and Saumya Shekhar Jamuar. Tfap2a mutation in a child and mother with predominantly ocular anomalies: non-classical presentation of branchio-oculo-facial syndrome. Clinical Dysmorphology, 28:215-218, Oct 2019. URL: https://doi.org/10.1097/mcd.0000000000000290, doi:10.1097/mcd.0000000000000290. This article has 2 citations and is from a peer-reviewed journal.
(thomeer2010clinicalpresentationand pages 4-6): Henricus G. X. M. Thomeer, Tom T. H. Crins, Erik J. Kamsteeg, Wendy Buijsman, Johannes R. M. Cruysberg, Nine V. A. M. Knoers, and W. R. J. Cremers. Clinical presentation and the presence of hearing impairment in branchio-oculo-facial syndrome: a new mutation in the tfap2a gene. Annals of Otology, Rhinology & Laryngology, 119:806-814, Dec 2010. URL: https://doi.org/10.1177/000348941011901204, doi:10.1177/000348941011901204. This article has 12 citations.
(haldemanenglert2025branchiooculofacialsyndrome pages 9-11): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.
(milunsky2011genotype–phenotypeanalysisof pages 7-7): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.
(lugli2015earlydiagnosisof pages 1-3): Licia Lugli, Walter Just, Elisabetta Genovese, Silvia Palma, Fabrizio Ferrari, and Antonio Percesepe. Early diagnosis of branchio-oculo-facial syndrome in a patient with inner ear malformation and mild ocular involvement. Clinical Dysmorphology, 24:17–20, Jan 2015. URL: https://doi.org/10.1097/mcd.0000000000000061, doi:10.1097/mcd.0000000000000061. This article has 1 citations and is from a peer-reviewed journal.
(milunsky2011genotype–phenotypeanalysisof pages 9-10): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.
(milunsky2011genotype–phenotypeanalysisof pages 6-7): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.
(reiber2010additionalclinicaland pages 3-5): Judith Reiber, Yves Sznajer, Elena Guillén Posteguillo, Dietmar Müller, Stanislas Lyonnet, Clarisse Baumann, and Walter Just. Additional clinical and molecular analyses of tfap2a in patients with the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 152A:994-999, Apr 2010. URL: https://doi.org/10.1002/ajmg.a.33331, doi:10.1002/ajmg.a.33331. This article has 31 citations.
(nguyen2024tfap2paralogsregulate pages 1-3): Timothy T. Nguyen, Jennyfer M. Mitchell, Michaela D. Kiel, Colin P. Kenny, Hong Li, Kenneth L. Jones, Robert A. Cornell, Trevor J. Williams, James T. Nichols, and Eric Van Otterloo. Tfap2 paralogs regulate midfacial development in part through a conserved alx genetic pathway. Development, Jan 2024. URL: https://doi.org/10.1242/dev.202095, doi:10.1242/dev.202095. This article has 17 citations and is from a domain leading peer-reviewed journal.
(nguyen2024tfap2paralogsregulate pages 7-9): Timothy T. Nguyen, Jennyfer M. Mitchell, Michaela D. Kiel, Colin P. Kenny, Hong Li, Kenneth L. Jones, Robert A. Cornell, Trevor J. Williams, James T. Nichols, and Eric Van Otterloo. Tfap2 paralogs regulate midfacial development in part through a conserved alx genetic pathway. Development, Jan 2024. URL: https://doi.org/10.1242/dev.202095, doi:10.1242/dev.202095. This article has 17 citations and is from a domain leading peer-reviewed journal.
(tacla2024molecularinvestigationin pages 1-2): Milena Atique Tacla, Matheus de Mello Copelli, Eleonore Pairet, Isabella Lopes Monlleó, Erlane Marques Ribeiro, Elaine Lustosa Mendes, Raphaël Helaers, Tarsis Paiva Vieira, Miikka Vikkula, and Vera Lúcia Gil-da-Silva-Lopes. Molecular investigation in individuals with orofacial clefts and microphthalmia-anophthalmia-coloboma spectrum. European journal of human genetics : EJHG, 32:1257-1266, Nov 2024. URL: https://doi.org/10.1038/s41431-023-01488-5, doi:10.1038/s41431-023-01488-5. This article has 5 citations.
(milunsky2011genotype–phenotypeanalysisof pages 7-9): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.
(haldemanenglert2025branchiooculofacialsyndrome pages 7-9): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.